Ketamine for Endoscopic Sedation in Outpatient Adult Endoscopy.
Status: | Recruiting |
---|---|
Healthy: | No |
Age Range: | 18 - 65 |
Updated: | 4/17/2018 |
Start Date: | March 5, 2018 |
End Date: | February 1, 2019 |
Contact: | Jerome C Edelson, MD |
Email: | jerome.c.edelson.mil@mail.mil |
Phone: | 210-220-0935 |
Ketamine as a Sedation Adjunct for Endoscopic Procedures
We will be investigating the use of ketamine in sedation for endoscopic procedures,
specifically outpatient endoscopy including esophagoduodenoscopy (EGD) and colonoscopy.
Participants will be randomized to one of two arms including conventional moderate sedation
with midazolam and fentanyl or the ketamine arm. They will then undergo the planned
procedure. Physicians preforming the procedure will be surveyed following the procedure and
patients will be surveyed twice, once after meeting criteria for discharge on day of the
procedure and a second time 48 hours following the procedure.
specifically outpatient endoscopy including esophagoduodenoscopy (EGD) and colonoscopy.
Participants will be randomized to one of two arms including conventional moderate sedation
with midazolam and fentanyl or the ketamine arm. They will then undergo the planned
procedure. Physicians preforming the procedure will be surveyed following the procedure and
patients will be surveyed twice, once after meeting criteria for discharge on day of the
procedure and a second time 48 hours following the procedure.
In this study, the investigators plan to conduct a single blinded randomized controlled trial
in the Gastroenterology Service to demonstrate the efficacy of ketamine and its utility in
moderate sedation. Patients presenting to the endoscopy lab for esophagogastroduodenoscopy
(EGD) and/or colonoscopy who meet inclusion criteria will be approached, and if amenable,
will be consented and enrolled. Patients will be randomized to receive either a ketamine
loading dose and then subsequent doses IV ketamine and midazolam 1mg IV prior to
administration of ketamine or standard fentanyl/midazolam moderate sedation during their
procedure. Participants will then undergo the planned procedure. The primary outcome will be
patient satisfaction, which will be measured using the validated "Patient Satisfaction with
Sedation" instrument (PSSI). A number of secondary outcomes will include the following: (1)
provider satisfaction (measured using and the "Clinician Satisfaction with Sedation"
instrument (CSSI), (2) the time from sedation administration to procedure start (when the
scope is inserted), (3) the time from sedation to recovery (defined as the time from the end
of the procedure until the patient meets discharge criteria from the recovery area), (4) time
to cecum (for colonoscopy) total doses of medications given (midazolam, fentanyl, and
ketamine), (5) overall time of the procedure, (6) adverse events, (7) changes in vital signs,
(8) and the need for additional medications, in particular reversal agents.
in the Gastroenterology Service to demonstrate the efficacy of ketamine and its utility in
moderate sedation. Patients presenting to the endoscopy lab for esophagogastroduodenoscopy
(EGD) and/or colonoscopy who meet inclusion criteria will be approached, and if amenable,
will be consented and enrolled. Patients will be randomized to receive either a ketamine
loading dose and then subsequent doses IV ketamine and midazolam 1mg IV prior to
administration of ketamine or standard fentanyl/midazolam moderate sedation during their
procedure. Participants will then undergo the planned procedure. The primary outcome will be
patient satisfaction, which will be measured using the validated "Patient Satisfaction with
Sedation" instrument (PSSI). A number of secondary outcomes will include the following: (1)
provider satisfaction (measured using and the "Clinician Satisfaction with Sedation"
instrument (CSSI), (2) the time from sedation administration to procedure start (when the
scope is inserted), (3) the time from sedation to recovery (defined as the time from the end
of the procedure until the patient meets discharge criteria from the recovery area), (4) time
to cecum (for colonoscopy) total doses of medications given (midazolam, fentanyl, and
ketamine), (5) overall time of the procedure, (6) adverse events, (7) changes in vital signs,
(8) and the need for additional medications, in particular reversal agents.
Inclusion Criteria:
- Patients age 18 to 65 years who present to the GI clinic for an EGD or colonoscopy
Exclusion Criteria:
- Poor vital sign stability
- Hypoxia: O2 < 92%,
- Hypotension, hypertension, heart rate and respiratory rates greater than 20% above or
below normal as dictated by normal ranges in SAMMC protocol
- Any allergy to ketamine, fentanyl, or midazolam
- Patient is pregnant or refuses pregnancy test, in women of child-bearing potential.*
- American Society of Anesthesiologists (ASA) score>3
- Presence of a history of psychosis, hallucinations, and/or a psychotic disorder
- History of increased intracranial pressure/ hypertensive hydrocephalus within the last
3 months
- Active pulmonary infection or disease.
- History of airway instability, tracheal surgery, or tracheal stenosis.
- * Not applicable if patient is a female over 50 years old or has had a
hysterectomy and/or oophorectomy
We found this trial at
1
site
3551 Roger Brooke Dr
Fort Sam Houston, Texas 78234
Fort Sam Houston, Texas 78234
(210) 916-4141
Phone: 210-220-0935
Brooke Army Medical Center Brooke Army Medical Center (BAMC) is the Flagship of Army Medicine!...
Click here to add this to my saved trials